Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016’, provides in depth analysis on Angiopoietin 2 (Ang 2 or ANGPT2) targeted pipeline therapeutics.

The report provides comprehensive information on the Angiopoietin 2 (Ang 2 or ANGPT2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Angiopoietin 2 (Ang 2 or ANGPT2)

The report reviews Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics and enlists all their major and minor projects

The report assesses Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Angiopoietin 2 (Ang 2 or ANGPT2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Angiopoietin 2 (Ang 2 or ANGPT2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

AnGes MG, Inc.

Boehringer Ingelheim GmbH

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

MedImmune, LLC

Regeneron Pharmaceuticals, Inc.

RXi Pharmaceuticals Corporation

Silence ...

Amgen Inc.

AnGes MG, Inc.

Boehringer Ingelheim GmbH

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

MedImmune, LLC

Regeneron Pharmaceuticals, Inc.

RXi Pharmaceuticals Corporation

Silence Therapeutics Plc

Synergys Biotherapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Angiopoietin 2 ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Angiopoietin 2 (Ang 2 or ANGPT2) Overview 7

Therapeutics Development 8

Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Stage of Development 8

Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Therapy Area 9

Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Indication 10

Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Companies 14

Angiopoietin 2 (Ang 2 or ANGPT2) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Angiopoietin 2 (Ang 2 or ANGPT2) - Companies Involved in Therapeutics Development 23

Amgen Inc. 23

AnGes MG, Inc. 24

Boehringer Ingelheim GmbH 25

Eli Lilly and Company 26

F. Hoffmann-La Roche Ltd. 27

MedImmune, LLC 28

Regeneron Pharmaceuticals, Inc. 29

RXi Pharmaceuticals Corporation 30

Silence Therapeutics Plc 31

Synergys Biotherapeutics, Inc. 32

Angiopoietin 2 (Ang 2 or ANGPT2) - Drug Profiles 33

(aflibercept + nesvacumab) - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

AG-30/5C - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Anti-Angiopoietin-1/2 Monoclonal Antibody - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Antisense RNAi Oligonucleotides to Inhibit Angiopoietin-2 for Retinal Disease and Oncology - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AP-202 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Atu-111 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

BI-836880 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

LY-3127804 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MEDI-3617 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

MEDI-3617 + tremelimumab - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Monoclonal Antibody to Inhibit Angiopoietin 2 for Oncology - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

RG-7716 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

trebananib - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

vanucizumab - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Angiopoietin 2 (Ang 2 or ANGPT2) - Dormant Projects 51

Angiopoietin 2 (Ang 2 or ANGPT2) - Discontinued Products 53

Angiopoietin 2 (Ang 2 or ANGPT2) - Featured News & Press Releases 54

Nov 04, 2014: Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer 54

Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 54

Jun 20, 2014: University of Arizona Cancer Center at St. Joseph’s researcher reports on response of a new treatment for ovarian cancer 55

Jun 12, 2013: Amgen's Phase III Trial Of Trebananib Meets Primary Endpoint In Recurrent Ovarian Cancer 56

Nov 28, 2012: CNIO Announces Initiation Of Phase I Clinical Trial Of New Anti-tumour Drug RO5520985 57

Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 57

Jan 24, 2011: Takeda Initiates Phase III Clinical Trials Of Anti-Cancer Agent AMG 386 In Japan 58

Jan 24, 2011: Takeda Initiates Phase III Clinical Trials Of Anti-Cancer Agent AMG 386 In Japan 58

Oct 09, 2010: Amgen Announces Phase II Trial Results Of AMG 386 In Patients With Recurrent Ovarian Cancer 59

Jun 06, 2010: Amgen's AMG 386 Demonstrates Promising Antitumor Activity In Patients With Recurrent Ovarian Cancer 59

Apr 13, 2008: Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules AMG 386 Suggests Biologic Activity Across Tumor Types 60

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of ...

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Amgen Inc., H2 2016 23

Pipeline by AnGes MG, Inc., H2 2016 24

Pipeline by Boehringer Ingelheim GmbH, H2 2016 25

Pipeline by Eli Lilly and Company, H2 2016 26

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 27

Pipeline by MedImmune, LLC, H2 2016 28

Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016 29

Pipeline by RXi Pharmaceuticals Corporation, H2 2016 30

Pipeline by Silence Therapeutics Plc, H2 2016 31

Pipeline by Synergys Biotherapeutics, Inc., H2 2016 32

Dormant Projects, H2 2016 51

Dormant Projects (Contd..1), H2 2016 52

Discontinued Products, H2 2016 53

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of ...

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports